Bomedemstat
Imago BioSciences
[]
imago biosciences presents positive data from ongoing phase 2 study of bomedemstat in essential thrombocythemia at eha 2022 $imgo 
Run by investors, for investors.

Real-time:
PRs
Gov. contract awards
Earnings
M&As
FDA approvals
Insider trades
SEC filings
And more

Not investment advice